Torm (NASDAQ:TRMD) reported a sharply stronger first quarter of 2026 and raised its full-year outlook, citing firm freight markets, geopolitical disruptions and what management described as the company’s operating advantages in a highly volatile tanker market.
Chief Executive Officer Jacob Meldgaar
Tower Semiconductor (NASDAQ:TSEM) reported a sharp year-over-year increase in first-quarter 2026 profit and issued guidance for what it said would be the highest quarterly revenue in the company’s history, driven by accelerating demand in silicon photonics and related technologies for AI data center
Regis (NASDAQ:RGS) reported higher profitability and positive cash flow in its fiscal third quarter of 2026, even as total revenue declined, as the salon franchisor pointed to cost controls, company-owned salon improvements and a sharper focus on its largest brands under new Chief Executive Officer
Sanuwave Health (NASDAQ:SNWV) reported record first-quarter revenue and rising consumables utilization, while management said the advanced wound care market began to recover after a difficult start to the year tied to changes in reimbursement for skin substitutes.
Chairman and CEO Morgan Frank said
PolyPid (NASDAQ:PYPD) said its first quarter marked a transition from late-stage clinical development toward regulatory submission and commercial preparation for D-PLEX100, its lead product candidate for preventing surgical site infections in abdominal colorectal surgery.
Chief Executive Officer Di
PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and reduce costs.
On the company’s first quarter 2026 earnings call, Chief Executive Officer Dr. Frank
Nebius Group (NASDAQ:NBIS) reported a sharply higher first quarter for 2026 as demand for AI computing capacity continued to outpace supply, prompting management to raise its capital spending plans and expand its long-term power commitments.
Co-founder and CEO Arkady Volozh said the company is buil
Nexxen International (NASDAQ:NEXN) reported record first-quarter results for the three months ended March 31, 2026, and raised its full-year revenue outlook, citing stronger programmatic advertising demand, renewed growth in connected TV and early traction from its enterprise sales strategy.
Chief
Milestone Pharmaceuticals (NASDAQ:MIST) said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular tachycardia, or PSVT, while the company also moved ahead with a Phase 3 program in atrial fibr
Plug Power's dramatic margin recovery and strategic execution are positioning it as a key leader in the hydrogen economy as it moves toward profitability.
